Oramed Pharma

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.

[Oramed Pharma @OramedPharma]

We're pleased to share this letter to shareholders, providing updates on the significant developments across Oramed's operations and strategic initiatives.
$ORMP

https://t.co/xCbfzFo9Qe

[Oramed Pharma @OramedPharma]

We're pleased to announce that Oramed will join the U.S. small cap Russell 2000® and broad-market Russell 3000® Index at the conclusion of the 2026 Russell indexes semi-annual reconstitution.

$ORMP

https://t.co/3ApXGsbbis

[Oramed Pharma @OramedPharma]

Oramed and Lifeward Announce Strategic Transaction - https://t.co/q6jti9DwKA Transaction Will Transfer Oramed’s Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder $ORMP

[Oramed Pharma @OramedPharma]

Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments - https://t.co/oT0mB47C4a $ORMP

[Oramed Pharma @OramedPharma]

Oramed Reports Fiscal Third Quarter 2025 Financial Results - https://t.co/v68TUuBUF5 Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million $ORMP

[Oramed Pharma @OramedPharma]

Oramed Releases Letter to Shareholders, Highlighting Developments in Oral Insulin Program, Significant Investment Appreciation - https://t.co/k3lxcPaBdS $ORMP

[Oramed Pharma @OramedPharma]

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical - https://t.co/gm1cw6uxAj $ORMP

[Oramed Pharma @OramedPharma]

Oramed Pharmaceuticals Issues Letter to Shareholders

https://t.co/We0vXmraB3 $ORMP

[Oramed Pharma @OramedPharma]

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin - https://t.co/BdWrRJSSrI $ORMP #drugdevelopment #oralinsulin

[Oramed Pharma @OramedPharma]

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - https://t.co/y8OGCAdLBC $ORMP

[Oramed Pharma @OramedPharma]

We're pleased to share this letter to shareholders from our CEO https://t.co/zFDiBf1AeA $ORMP

[Oramed Pharma @OramedPharma]

This week we hosted colleagues from HTIT for ongoing discussions on our Joint Venture. We look forward to working together to bring oral insulin to market in China and beyond.
$ORMP #JV #Oralinsulin #Biotech

[Oramed Pharma @OramedPharma]

Oramed to Present at 83rd American Diabetes Association Conference - https://t.co/RQtyy3UHNm
$ORMP #oralinsulin #ADA #T2D #NASH

[Oramed Pharma @OramedPharma]

Oramed announces its Chinese partner successfully completed a Phase 3 oral insulin trial and that Oramed has completed an analysis of its U.S.-based Phase 3 oral insulin trial with significant lowering of A1C levels seen in patient subgroups - https://t.co/R8xe7U9mag
$ORMP

[Oramed Pharma @OramedPharma]

“We're excited to welcome @benshapiro onto our Board of Directors. His talents are expected to bring real value to the @OramedPharma Board and we're delighted to work with him to build shareholder value,” said Oramed CEO, Nadav Kidron.

https://t.co/rtLW9Xl8d3

[Oramed Pharma @OramedPharma]

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin - https://t.co/rRwH5QPLy5
With topline data for our first Phase 3 oral insulin trial expected soon, we continue to fortify Oramed’s leading position with respect to intellectual property assets
$ORMP #biotech

[Oramed Pharma @OramedPharma]

Oramed Letter to Shareholders - https://t.co/JK94RnwS3D
We are entering 2023 with real excitement for what we believe will be a monumental year for the Company starting with expected topline #data from the first of our two P3 #oralinsulin trials in mid-Jan. $ORMP #biotech

[Oramed Pharma @OramedPharma]

Check out the highlight video of Oramed’s recent webinar sharing data from its positive phase 2 clinical trial of oral insulin for #NASH with a Key Opinion Leader Discussion on the current treatment landscape.
You can see the entire webinar here: https://t.co/TtZF4eoEks

$ORMP

[Oramed Pharma @OramedPharma]

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism - https://t.co/u2xJGuzWKG The article can be accessed on Oramed's website under Scientific Articles and Abstracts.
$ORMP #oralinsulin #biotech

[Oramed Pharma @OramedPharma]

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH - https://t.co/dVTaXW6Suo
The presentation of this new data was featured in a webinar today with a replay available on Oramed’s website.
$ORMP #NASH #Biotech